Mismatch Repair Deficiency clinical trials at UC Irvine
1 research study open to eligible people
Showing trials for
RP1 Monotherapy and RP1 in Combination With Nivolumab
open to eligible people ages 18 years and up
RPL-001-16 is a Phase 1/2, open label, dose escalation and expansion clinical study of RP1 alone and in combination with nivolumab in adult subjects with advanced and/or refractory solid tumors, to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.
Orange 5379513, California 5332921 and other locations
Our lead scientists for Mismatch Repair Deficiency research studies include John Fruehauf, MD.
Last updated: